Physician profile
Sara H Steelman
NPI 1992759591
$640.53
in general payments reported to CMS, 2019-2025
14 companies · $151 in 2025
The $151 reported for 2025 was more than what a typical Pediatric Emergency Medicine (Emergency Medicine) provider received nationally (typical 2025 total: $57.68).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $116 · 2020: $59.43 · 2021: $37.00 · 2022: $129 · 2023: $50.54 · 2024: $97.19 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $298.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $125.32 | 2020-2024 | Kcentra |
| Janssen Pharmaceuticals, INC | $83.42 | 2019-2021 | |
| Gilead Sciences, INC. | $58.55 | 2022-2024 | Veklury |
| Vertex Pharmaceuticals Incorporated | $56.80 | 2025 | |
| Portola Pharmaceuticals, LLC | $53.82 | 2019-2020 | |
| Abbvie INC. | $45.11 | 2022-2024 | |
| Stryker Corporation | $40.26 | 2025 | Flowtriever |
| Inari Medical, INC. | $33.98 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Astrazeneca Pharmaceuticals Lp | $32.40 | 2019-2025 | Fasenra |
| Melinta Therapeutics, LLC | $30.09 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $22.86 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.73 | 2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $20.78 | 2019 | |
| Grifols USA, LLC | $14.41 | 2025 | Hyperrab |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Steelman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.